Avapro Tablet, Film Coated
Product Images NDC 0024-5852

6 FDA label images from Sanofi-aventis U.s. Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Avapro (NDC 0024-5852). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (7885b2a8 Be4e 48ab 8113 4e6ab791eb98 01)

Chemical Structure (7885b2a8 Be4e 48ab 8113 4e6ab791eb98 01)
Chemical structure of irbesartan, the active ingredient in Avapro, a human prescription oral film-coated tablet produced by Sanofi-Aventis U.S. LLC. The structure depicts the molecular arrangement and key functional groups characteristic of irbesartan.*
FDA Label Image

Figure 1 (7885b2a8 Be4e 48ab 8113 4e6ab791eb98 02)

Figure 1 (7885b2a8 Be4e 48ab 8113 4e6ab791eb98 02)
A scatter plot with a dose-response curve illustrating the relationship between irbesartan dose (mg/day) on the x-axis and the placebo-subtracted reduction in trough SeSBP (mmHg) on the y-axis. The graph shows increasing effect with higher doses up to around 300 mg/day, then a plateau.*
FDA Label Image

Figure 2 (7885b2a8 Be4e 48ab 8113 4e6ab791eb98 03)

Figure 2 (7885b2a8 Be4e 48ab 8113 4e6ab791eb98 03)
A dose-response curve chart showing the placebo-subtracted reduction in trough SeDBP (mmHg) plotted against the irbesartan dose in mg/day, illustrating increasing effect with higher doses up to around 900 mg/day.*
FDA Label Image

Figure 3 (7885b2a8 Be4e 48ab 8113 4e6ab791eb98 04)

Figure 3 (7885b2a8 Be4e 48ab 8113 4e6ab791eb98 04)
A cumulative event rate line graph comparing Avapro, Amlodipine, and placebo over 60 months of follow-up. The y-axis shows cumulative event rate percentages, and the x-axis represents months of follow-up. Avapro, Amlodipine, and placebo are depicted with distinct line styles. A data table inset provides relative risk (RR) and p-values comparing Avapro with placebo and Amlodipine.*
FDA Label Image

Principal Display Panel (150 mg Tablet Bottle Label)

Principal Display Panel (150 mg Tablet Bottle Label)
Avapro (irbesartan) Tablets 150 mg film-coated oral tablets, packaged in a container of 30 tablets. The label includes the Sanofi logo and identifies Sanofi-Aventis U.S. LLC as the labeler. The NDC is 0024-5851-30. Additional text provides storage conditions and regulatory information.*
FDA Label Image

Principal Display Panel (300 mg Tablet Bottle Label)

Principal Display Panel (300 mg Tablet Bottle Label)
Avapro (irbesartan) Tablets 300 mg film-coated tablet label showing a package size of 30 tablets. The label includes dosage strength, NDC 0024-5852-30, bar code, manufacturer Sanofi-Aventis U.S. LLC, and storage instructions for controlled room temperature.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.